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Opioids that stimulate the m-opioid receptor (MOR1)
are the most frequently prescribed and effective
analgesics. Here we present a structural model of
MOR1. Molecular dynamics simulations show a
ligand-dependent increase in the conformational
flexibility of the third intracellular loop that couples
with the G protein complex. These simulations like-
wise identified residues that form frequent contacts
with ligands. We validated the binding residues
using site-directed mutagenesis coupled with radio-
ligand binding and functional assays. The model was
used to blindly screen a library of 1.2 million
compounds. From the 34 compounds predicted to
be strong binders, the top three candidates were
examined using biochemical assays. One compound
showed high efficacy and potency. Post hoc testing
revealed this compound to be nalmefene, a potent
clinically used antagonist, thus further validating
the model. In summary, the MOR1 model provides
a tool for elucidating the structural mechanism of
ligand-initiated cell signaling and for screening novel
analgesics.
INTRODUCTION
Opioid analgesics are the most widely used drugs to treat
moderate to severe pain (Inturrisi, 2002; Terrell et al., 2010). Mu-
opioid receptors (MOR) in the peripheral and central nervous
system are the primary target of exogenous opioid analgesics
(Matthes et al., 1996; Reisine and Pasternak, 1996; Sora et al.,
1997; Uhl et al., 1999). MOR agonists, such as morphine, exert
their analgesic effects by stimulating MOR receptors leading to
the initiationof presynaptic andpostsynaptic inhibitory processes
that decrease the electrical excitability and neurotransmitter
release (Inturrisi, 2002;North, 1986;ReisineandPasternak, 1996).
MOR receptors are members of the G protein-coupled
receptor (GPCR) family. Canonical MOR signaling involves acti-
vation of inhibitory G-proteins (Gai/o) that leads to the dissocia-Structure 19, 1683–16tion of the heterotrimeric G protein complex. The release of the
Ga subunit inhibits adenyl cyclase (AC) and the release of Gbg
subunits activate K+ channels and inhibit voltage-gated Ca2+
channels (VGCC) with AC-dependent decreases in cAMP levels
being the most direct and immediate cellular event (Figure 1A)
(Inturrisi, 2002; Reisine and Pasternak, 1996).
GPCRs are integral membrane proteins that exhibit conserved
seven membrane-spanning helices, although the orientation of
these helices may differ from one subfamily to another (Kobilka
and Deupi, 2007). Because GPCRs are involved in major signal
transduction pathways and also represent a major drug target,
the modeling of their structure and function has been a major
focus in the area of computational drug discovery (Ballesteros
and Palczewski, 2001; Becker et al., 2004; Michino and Brooks,
2009). As such, three-dimensional modeling efforts have been
applied to the major MOR isoform MOR1 (Alkorta and Loew,
1996; Filizola et al., 1999b; Filizola and Weinstein, 2002; Jordan
and Devi, 1999; Strahs and Weinstein, 1997). Models of MOR1
(Alkorta and Loew, 1996; Filizola et al., 1999b; Strahs and Wein-
stein, 1997) have been constructed based on the X-ray structure
of bovine rhodopsin (Palczewski et al., 2000), the first GPCR
structure identified using X-ray crystallography. Although these
models have been insightful, the further study of molecular
dynamics (MD) that underlie ligand-receptor binding and the
development of high throughput screening assays that will
permit the identification of novel MOR ligands require higher
resolution models. Moreover, understanding the structural basis
of how MOR1 ligands engage G-proteins remains an open
question.
In this study, we report the development of a high-resolution
structural model of the MOR1. This structural model is in agree-
ment with prior biochemical and pharmacological studies and
is further confirmed using site-directed mutagenesis that
identified critical ligand-binding residues. Molecular dynamics
simulation of the receptor with and without morphine showed
that the ligand binding leads to greater flexibility of the third
intracellular loop, which is in agreement with the downstream
protein complex interactions and signaling pathways activated
by receptor agonists (Waldhoer et al., 2004). Finally, using our
model, we have also conducted a virtual screening of a chemical
library that consists of lead small molecular weight compounds
to identify putative compounds that show strong binding to
MOR1.90, November 9, 2011 ª2011 Elsevier Ltd All rights reserved 1683
Figure 1. MOR1 Structural Model and Potential Mechanism for G Protein Activation
(A) Opioid drug binding to MOR1 activates the coupled G protein-effector, inhibiting adenyl cyclase, and downstream cAMP signaling cascades.
(B) Structural model of the receptor modeled from bovine rhodopsin exhibiting the seven-transmembrane topology conserved among GPCRs. N and C termini
are colored blue and red, respectively.
(C) We performed MD simulation to investigate the stability and dynamics of the structure in the presence and absence of morphine. Plot of the per residue root-
mean-square fluctuation (rmsf) to investigate the flexibility of various segments of the protein during the simulation. Arrows indicate the regions that change
flexibility in the presence of morphine. The intra- and extracellular loops exhibit the greatest variability; most noteworthy are i3 and e3. The rmsf values are
mapped into the protein structure. Backbone thickness and color is proportional to the rmsf values, thicker regions and warmer colors reflect greater flexibility
whereas narrower regions and cooler colors reflect less flexibility.
See also Figure S1 and Table S1.
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Structural Modeling and Effect of Ligands on Receptor
Dynamics
GPCR structures exhibit seven transmembrane helices whose
overall topological fold is conserved.We constructed preliminary
structural models using five known crystal structures of GPCRs:
bovine rhodopsin (Protein Data Bank [PDB] ID: 1u19), squid
rhodopsin (PDB ID: 2z73), b1-adrenergic receptor (PDB ID:
2vt4), b2-adrenergic receptor (PDB ID: 2rhi), and A2A adenosine
receptor (PDB ID: 3eml) (see Experimental Procedures). The
quality of the initial models was evaluated using Molprobity,
which evaluates the accuracy of macromolecular structures
through analysis of contacts and evaluation of dihedral angle
combinations (Davis et al., 2007). Among the preliminarymodels,
we found that the best candidate for further optimization to be
the model constructed from bovine rhodopsin. This model was
then revised to eliminate the invalid geometry, a procedure that
was repeated until we arrived at a model whose backbone and
side-chain geometry is comparable to GPCR crystal structures
(Figure 1B; see Table S1 available online). We required themodel
accuracy be comparable to the experimental GPCR structures
because of the strongly conserved topology of the protein espe-
cially in the transmembrane region. This requirement implies that
the model is accurate enough for drug screening (see below).
In the extracellular loop, we imposed that the model features
the highly conserved disulfide bond between C1423.36-C219
(numeric superscripts throughout the text indicate the Wein-
stein-Ballesteros convention of naming GPCR residues [Balles-
teros and Weinstein, 1995]).
Additional validation of the model comes from docking
morphine to the model structure and comparing the identified1684 Structure 19, 1683–1690, November 9, 2011 ª2011 Elsevier Ltdbinding-pocket residues with prior mutagenesis and binding
studies. To initially validate the residues that comprise the
binding site, we mapped the sites to whose mutations have
been shown previously to either affect or not affect morphine
binding (Figure S1). For example, mutating D1162.50 in (TM2)
to asparagine and Y3287.43 (TM7) to phenylalanine has shown
to significantly reduce morphine-binding by 100- to 1000-fold
(Raynor et al., 1994; Surratt et al., 1994). As shown in the
model, D1162.50 and Y3287.43 mediate morphine binding in
the putative binding site. Known mutations in the protein
that do not significantly influence ligand binding are generally
either far or have side chains pointing away from the ligand-
binding pocket, suggesting that they may not be as critical in
forming the binding pocket (Figure S1B). These mutations
include V128A2.62 in TM2; T139E3.23, I140L3.24, I146A/L3.30,
and N152A3.36 in TM3; I200V4.56 and V204I4.60 in TM4; K235R/
A/H/L5.39 in TM5; and H299Q/N6.52 in TM6. The putative binding
pocket was further validated by our own mutagenesis studies
(see below).
To evaluate the structural integrity of the model, we performed
all-atom MD simulation of the model structure in GROMACS
(Lindahl et al., 2001) using a modified Gromos96 force field
for the protein, lipid, and morphine (Chandrasekhar et al.,
2003; Oostenbrink et al., 2005; Schu¨ttelkopf and van Aalten,
2004) (see Experimental Procedures for details). Indeed, from
the 20 ns of equilibrium MD simulation, we observed that
the protein is stable with root-mean-square deviation (rmsd)
stabilized within 3.5 A˚, indicating no major structural clashes or
unnatural protein interactions in the model (Figure S2). Such
values of equilibrium rmsd have also been observed in simula-
tions of GPCR structures derived from X-ray, such as bovine
rhodopsin (Schlegel et al., 2005) and A2A adrenergic receptorAll rights reserved
Figure 2. Binding Pocket of MOR1 Receptor and Targeted Mutagenesis
(A) Shown are residues within the 4.5 A˚ of the boundmorphine. Side chains are colored according to their contact probability, which is defined as the likelihood of
interacting with morphine during the simulation run. Contact probability of 1 indicates that the specific residue is always within 4.5 A˚ of morphine, whereas
0 indicates that the residue is always beyond 4.5 A˚ of morphine.
(B) To validate the predicted residues near the binding site, we choose mutations that were predicted to disrupt morphine and diprenorphine binding. The
receptor locations of the mutated residues are listed, TM is coded for helix and e is coded for extra-cellular loop. **p < 0.0001 and *p < 0.05 different fromMOR1
WT. Numeric superscripts indicate the Weinstein-Ballesteros convention of naming GPCR residues (Ballesteros and Weinstein, 1995).
See also Figure S2 and Table S3.
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tion to a minimum energy state.
We next computed the average root-mean-square fluctua-
tions of each residue, which quantifies the local conformational
flexibility (Figure 1C). Expectedly, the extracellular and intracel-
lular loop regions are the most flexible and the membrane-
embedded regions are the least flexible. The most dynamic
regions are the third intracellular loop i3 and C terminus of the
receptor, which has also been shown to be very flexible from
comparison of various experimental structures of other GPCR
proteins (Cherezov et al., 2007; Jaakola et al., 2008; Murakami
and Kouyama, 2008; Rosenbaum et al., 2007; Spivak et al.,
1997; Warne et al., 2008). The increased flexibility of the loop
i3 observed in our simulation of MOR1 may be related to the
rearrangement of helices TM5 and TM6 (both connected by i3)
in the adrenergic receptor as this GPCR switches from active
to inactive conformation (Rasmussen et al., 2011).
To investigate the effects of bound ligands on the equilibrium
dynamics of the receptor, we performed a similar simulation of
the MOR1 structure with bound morphine. We found that the
presence of ligand dramatically changed the flexibility of the i3
region and the distal end of the C terminus (Figure 1C), consis-
tent with the critical role of both the i3 and the C terminus in G
protein binding and cell signaling (Hanson and Stevens, 2009;
Waldhoer et al., 2004; Milligan and White, 2001).
Identifying Residues Critical for Ligand Binding
In order to utilize the in silico structural model to identify high-
affinity ligands using structure-based drug screening methods,Structure 19, 1683–16it is crucial to accurately model the ligand binding pocket of
the receptor. From the MD simulations of MOR1 receptor with
morphine, a widely clinically used opioid agonist, we identified
the residues that have high frequency contacts with the ligand
(Figure 2A). We surmise that these residues are critical for the
ligand binding. To validate these predictions and the model,
we generated single residue mutants to perturb interaction
with morphine (Figure 2B). All mutations were designed to be
conservative, with the goal of substantially diminishing ligand
bindingwithout affecting the overall protein folding or processing
(Figure 2B).
We then experimentally characterized the ligand binding
properties of the receptor mutants and their sensitivity to
morphine-dependent cAMP inhibition (Figures 2B and 3). Muta-
tion-dependent changes in ligand affinity were assessed by
determining the Kd values of corresponding mutants obtained
using a homologous competition binding assay with 1 nM
[3H]diprenorphine. [3H]Diprenorphine was chosen as a probe
because it is structurally similar to morphine and it is be insensi-
tive to any alterations in constitutive receptor-G protein coupling
caused by the mutations. Compared to morphine, the model
predicted that diprenorphine showed similar residues with high
frequency contacts.
To assess changes in morphine potency due to mutations, we
determined the EC50 values obtained via a bioluminescent assay
that measured morphine dose-dependent inhibition of intracel-
lular cAMP levels using a cAMP-sensitive luciferase reporter.
Inhibition of stimulated cAMP production was chosen as a most
direct functional assay to measure the morphine-dependent90, November 9, 2011 ª2011 Elsevier Ltd All rights reserved 1685
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Figure 3. Binding Affinity and Potency of MOR1 Mutants
HEK293T cells transiently transfected with MOR1 wild-type (WT-MOR1) or MOR1 mutants expressing constructs were subjected to (A and B) competitive
radioligand binding assay or (C and D) cAMP-sensitive luciferase reporter assay. The effect of mutations specific for e2 and TM5 domains (A and C) are shown
separately from the effect of mutations specific for TM3 and TM6 domains (B and D). (A and B) Increasing concentrations of MOR1 antagonist diprenorphine,
ranging from 1014 to 1012 M were applied with uniform 1 nM 3H-diprenorphine to determine Kd for each mutant and Kd fold change (F.C.) relative toWT-MOR1.
Statistically significant fold changes in Kd ranged from 3.13 (L221S) to 77.9 (M153S). (C and D) Increasing concentrations of morphine, ranging from 10
14 to
1012 Mwere applied to isoproterenol (100 nM) pretreated cells to inhibit cAMP production and determine EC50 and EC50 fold-change (F.C) relative toWT-MOR1.
Cotreatment of morphine withMOR1 antagonist naloxone damped the inhibitory effect of morphine. Significant fold-changes in EC50 ranged from 2.47 (F223A) to
80.72 (I298A). N/A: cAMP assay was failing due to very low baseline cAMP levels.
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m-Opioid Receptor Binding and Activationactivation of MOR1-Gai/o complex and subsequent inhibition of
AC (Inturrisi, 2002;ReisineandPasternak, 1996) (Figures1and3).
Compared to wild-type (WT-MOR1), the Kd values of the
receptor mutants decreased up to 78-fold (M153S3.37). Similarly,
EC50 values exhibited up to 80-fold decrease (I298A
6.51) in effi-
cacy. In general, we observed strong correlation between
changes in Kd and EC50 values in all mutants except one, which
shows stronger affect on potency. The Bmax for all the mutants
showed comparable values suggesting no effect on receptor
expression. Comparison of the Kd and EC50 values for WT-
MOR1 with the Kd and EC50 values for the mutants in the TM3
and TM6 revealed most robust reduction in ligand binding and
morphine potency. Two of the three mutants in the e2 loop
(L221S, F223A) also show significantly weaker ligand binding
compared to WT-MOR1 (3 fold difference in Kd values and
15- and 2.5-fold difference in EC50 values, respectively). The
observed effect of e2 point mutations were more modest than
those in the transmembrane helices, this is probably due to
the greater conformational flexibility of e2 loop compared to
the TM helices (Figure 1C). A greater conformational flexibility
would allow conformational rearrangement to accommodate
the ligand, thus dampening the effects of the mutation. Thus,
our ability to detect any significant effects is supportive of the
correct mapping of the contact residues L221S and F223A and1686 Structure 19, 1683–1690, November 9, 2011 ª2011 Elsevier Ltdmodel in general. It is also noteworthy that in the published struc-
tures of rhodopsin, adrenergic, and adenosine GPCRs, the e2
loop is topologically divergent, highlighting a potential important
role for the e2 loop in dictating ligand specificity.
In contrast, the I240A mutation in TM5 did not significantly
alter ligand affinity and potency, suggesting that the sequence
of TM5 during the homology modeling was possibly misaligned
and is consistent with the fact that sequence alignment can be
a challenge in homology modeling. Alternatively, it is plausible
that the I240Amutation was too conservative to significantly per-
turb ligand binding, thus a less conservative mutation at the 5.44
locus would better reveal whether I240 participates in morphine
binding as predicted in the model.
Virtual Screening for MOR1 Binding Ligands
Using the MOR1 structure models, we then computationally
screened a chemical compound library consisting of 1,296,388
ZINC compounds (Irwin and Shoichet, 2005) for novel ligands
predicted to bind the MOR1 receptor (Figure 4A). We computa-
tionally docked each compound onto the MOR1 structure and
estimated its binding affinity based on docking poses. To select
the best hits, we first ranked all compounds based on the pre-
dicted binding affinities and then visually inspected the electro-
static contacts of the top 100 compounds. The criteria forAll rights reserved
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Figure 4. Virtual Screening and Binding Affinity and Potency of Nalmefene
(A)We screened a library of1.3Mcompounds (ZINC) (Irwin and Shoichet, 2005) using theMOR1model and Autodock (Morris et al., 2009).We visually inspected
the docking poses of the top scoring ligands and select the ligands that have reasonable poses and electrostatic contact with the target.
(B) We found several target hits that include opioid-like compounds such as (nalmefene [Revex], ZINC22129845).
(C and D) HEK293 cells transiently transfected with MOR1 expressing constructs were subjected to (C) competitive radioligand binding assay or (D) cAMP-
sensitive luciferase reporter assay. (C) Increasing concentrations of nalmefene, diprenorphine, and naloxone were applied with uniform 1 nM 3H-diprenorphine
to determine Ki. The Ki for nalmefene, diprenorphine, and naloxone are 1.303, 2.128, and 57.40 nM, respectively, which are statistically different from each other
(p < 0.0002). (D) Cells were then treated with 100 nM isoproterenol and 1 mMmorphine for another 10min. EC50 values for nalmefene, diprenorphine and naloxone
are 2.05 nM, 12.64 nM, and 168.00 nM, which are statistically different from each other (p < 0.0001).
See also Table S2 and Table S4.
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of rotatable bonds, and the cluster size of the docking poses.
Ligands with smaller number of rotatable bonds have less
entropic penalty upon binding, whereas those with larger cluster
size of docking poses are dynamically more favorable. We took
extra account of these effects because they are not included in
the original binding energy prediction. Our final selection
included four ligands that satisfy all criteria and additional 30
ligands that ranked top according to electrostatic matching,
number of rotatable bonds, or cluster size. Out of these four
selected ligands, three were available from commercial sources
(Table S2). We screened these three compounds for both
binding affinity and receptor potency using receptor binding
and cAMP inhibition assays. One of these three compounds
(ZINC22129845) showed strong binding (Ki = 1.303 nM) and
antagonist properties (IC50 = 11.28 nM, in the presence of
1 mM of morphine). Post hoc testing revealed this compound
to be nalmefene (Revex), a recent potent opioid receptor antag-
onist that is used in the clinical setting (Figure 4). The blind
identification of a known potent MOR1 antagonist further vali-
dates the accuracy of the binding pocket predicted by the
model. Importantly, we would like to stress that even thoughStructure 19, 1683–16we identified a known opioid antagonist, our study was not retro-
spective, because we identified this compound in an unbiased
screening using formal criteria.
We inspected the docking poses of all 34 ligands and
observed that the ligand-binding sites are located between
TM3, TM5, TM6, and TM7. Although the binding site location is
consistent with our knowledge of other GPCR structures, the
detailed binding motif associated with our model is quite
different. The major interaction of the docking poses is the salt-
bridge between the amine group and an aspartate in TM3, and
hydrophobic interaction with TM5, TM6, and TM7. The binding
pose is also deeper into the receptor than the known binding
motif in rhodopsin, b1-adrenergic receptor, b2-adrenergic
receptor, and A2A adenosine receptor (Hanson and Stevens,
2009). The deeper binding pose associated with MOR1, when
compared with other GPCR ligands, permits small compounds
like morphine to penetrate deeper into the binding pocket.
We also reevaluated the binding affinity of some known MOR
ligands using a flexible-receptor docking and scoring protocol
(Ding et al. 2010; Yin et al., 2008). We used MedusaScore (Yin
et al., 2008) to approximate the binding energy for nalmefene,
which resulted in a predicted MedusaScore of 51.6 kcal/mol.90, November 9, 2011 ª2011 Elsevier Ltd All rights reserved 1687
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the criteria for best docking energies (Table S2). In comparison,
the predicted MedusaScore for morphine is 44.3 kcal/mol. We
also calculated the predicted MedusaScore for two other widely
used MOR1 antagonists, naloxone and diprenorphine, as well
as experimentally identified their Kd and IC50 values relative to
nalmefene. The MedusaScore for naloxone was 50.3 kcal.
The lower MedusaScore of diprenorphine (62.2 kcal/mol)
compared to nalmefene (51.6 kcal/mol) is due to a larger clash
energy (37.9 kcal/mol for diprenorphine and 17.8 kcal/mol
for nalmefene), which is not included in MedusaScore. The
MedusaScore difference between naloxone and nalmefene
qualitatively agrees with the experimental observation of their
binding potency and efficacy (Figures 4C and 4D), confirming
the superior potency of nalmefene. Furthermore, nalmefene
showed significantly greater binding and potency than both
naloxone and diprenorphine (Figures 4C and 4D).
To verify the robustness of our model to discriminateMOR1
ligands from non-ligands, we examined if there are other known
MOR1 ligands in the library apart from nalmefene. We searched
the screening library for compounds similar to morphine with
a Tanimoto coefficient >0.5, and found 21 morphine analogs
(Table S4). Tanimoto coefficient measures the similarity between
two compounds based on the presence or absence of molecular
fragments (Shivakumar and Krauthammer, 2009). We then used
the structures of thesemorphine analogs to query PubChem and
the ZINC database for their biological activities. We found that
among the morphine analogs, nalmephene was the only known
MOR1 ligand among them. This result is not surprising because
we used a ‘‘lead-like’’ compound library for screening whereas
mostMOR ligands are not ‘‘lead-like.’’ Notably three compounds
(ZINC22065588, ZINC16940005, and ZINC17130997) were
identified that are chemically more similar to morphine than nal-
mefene, yet they are not known to bind MOR1. Our virtual
screening also ranked them much lower than nalmefene, which
further demonstrates the capability of our structural model to
discriminate putative MOR1 ligands from non-MOR1 ligands.
DISCUSSION
MOR1 is a major pharmacological target for opioid analgesics,
yet our knowledge related to this receptor’s structure andmech-
anisms of activation and signaling are limited. In addition to the
basic molecular biological and pharmacological significance,
our findings are of clinical importance because >30% of patients
treated with opioids report inadequate pain relief (Ballantyne and
Shin, 2008; Noble et al., 2010) and thus the search for effective
and safe opioids remains a pressing clinical need. The produc-
tion of an accurate and detailed receptor model is one of the first
necessary steps in this endeavor. Key questions include deter-
mining the map of receptor-ligand interactions as well as the
structuralmechanismbywhich a receptor switches fromaquies-
cent to an active state and transmit extracellular signals to intra-
cellular effectors. Modeling receptor structure and dynamics is
crucial if we are to adequately address these key questions.
GPCRmodeling efforts have been applied toMOR1 previously
(Alkorta and Loew, 1996; Filizola et al., 1999b; Filizola and Wein-
stein, 2002; Strahs and Weinstein, 1997). Filizola et al. (1999a,
1999b) constructed a homology model of the MOR1 receptor1688 Structure 19, 1683–1690, November 9, 2011 ª2011 Elsevier Ltdusing the rhodopsin structure and performed a 500-ps uncon-
strained MD simulation to relax and evaluate the stability of the
structure. Although the model correctly suggested that the
MOR1 binding cavity is located in an inner inter-helical region
constituted by transmembrane helices TM3, TM4, TM5, TM6,
and TM7, and is partially covered by dynamic extracellular loops,
the accuracy of the model was limited by the availability of muta-
tional studies, short MD simulation, and absence of models of
the extra- and intracellular loops (Filizola et al., 1999b). More
recently, Zhang et al. (2005) constructed another homology
model of the MOR1 receptor, also from rhodopsin, and per-
formed a 2-ns MD simulation using a membrane-aqueous
system. Liu et al. (2009) also used MD simulation to study the
potential binding modes of several endomorphics. These
modeling efforts have been insightful but did not examine the
effects of ligand binding on receptor dynamics, a crucial issue
in understanding receptor function.
To address these critical issues, we built a new structural
model of the MOR1 receptor using the bovine rhodopsin
receptor. The model agrees with prior mutational studies on the
MOR1 receptor (FigureS1). Inaddition,wegeneratedapredictive
interaction map between the ligand and the receptor, which
we subsequently validated experimentally by targeted mutagen-
esis (Figures 2 and 3). All but two mutations we identified and
tested significantly reduced ligand potency and efficacy, illus-
trating the accuracy of our in silico predictive model.
To investigate the structural mechanism by which ligand
binding to the receptor is transformed into cellular signaling,
we performed simulations of the receptor dynamics in the
absence and presence of ligand (Figure 1C). We found that the
flexibility of intracellular loop i3 dramatically changes when
morphine is bound to the receptor, consistent with the critical
role of i3 as the docking site of G-proteins binding. The increased
flexibility of i3 morphine-bound state could serve as a structural
activator or a ‘‘mechanical signal’’ coupling the receptor and
G protein, which further initiates the signaling cascade as
proposed in earlier experimental studies (Hanson and Stevens,
2009; Waldhoer et al., 2004). Although the role of i3 in coupling
the receptor and the G protein has been known, the molecular
structural details of how this coupling arises in the absence or
presence of ligand was unknown. Furthermore, morphine-
dependent modulation of C terminus flexibility is also in agree-
ment with the critical role of C terminus in GPCRs signaling as
a structural site for phosphorylation and a binding site for scaf-
folding proteins (Milligan and White, 2001). Thus, our results
provide a structural basis for the MOR1 ligand initiated signaling
and a tool to study these structural mechanisms. Furthermore,
whereas other GPCRs vary in the length and conformation of
their i3 and C terminus, the structural basis of their activation
upon ligand binding could be a universal mechanism.
We also used the model structure to virtually screen 1.3
million compounds in the ZINC library for novel MOR1 ligands
(Figure 4). Among the top hits (Rank 1; Table S2), we blindly iden-
tified a morphine-like compound (nalmefene) that has potent
MOR1 binding and antagonistic properties, validating our model
of the binding pocket. Using this model receptor-drug complex,
we computationally predicted the binding affinities of nalmefene,
naloxone and morphine to be 55.7 kcal/mol, 49.3 kcal/mol,
and 42.3 kcal/mol, respectively, all in qualitative agreementAll rights reserved
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further confirming the accuracy of the model. Additionally, nal-
mefene, one of the 34 hits identified in the high throughput com-
putational screen and one of the three compounds screened
in the cellular assays, showed very strong binding characteristics
to the buildMOR1model andwas a stronger antagonist of MOR1
than naloxone and diprenorphine (Figures 4C and 4D). This
finding suggests that further screening of the selected com-
pounds is likely to yield other high potency MOR1 ligands.
In summary, we have constructed a structural model of MOR1
opioid receptor of high resolution and accuracy. The employ-
ment of MD simulations allowed us to show a morphine-depen-
dent increase in i3 intracellular loop flexibility and to determine
residues that have high frequency contacts with MOR1 ligands.
Subsequent use of the developed MOR1 structure model to
computationally screen a large chemical compound library
yielded a number of novel ligands predicted to bind the receptor
with high potency. Thus, our results offered new structural
insights in MOR1 ligand binding and receptor activation and
provided a tool for both studying the structural mechanism of
MOR1 ligand initiated cell signaling and in silico screening for
novel opioids that can produce high potency analgesia.
EXPERIMENTAL PROCEDURES
Structural Modeling and Molecular Dynamics Simulation
We used CLUSTALW to determine initial sequence alignment between human
MOR1 (Accession ID: P35372) and GPCR templates, bovine rhodopsin (PDB
ID: 1u19), squid rhodopsin (PDB ID: 2z73), b1-adrenergic receptor (PDB ID:
2vt4), b2-adrenergic receptor (PDB ID: 2rhi), and A2A adenosine receptor
(PDB ID: 3eml). Model construction was performed in the MODELER suite of
InsightII (Accelrys, San Diego). Models were evaluated for correct protein
geometry using Molprobity. Themodel building and evaluation was performed
recursively until we arrived at reasonable models of MOR1 (Table S2).
We performed MD simulations using GROMACS (Lindahl et al., 2001) with
the Gromos96 force field modified with additional parameters for lipids and
morphine (Chandrasekhar et al., 2003; Oostenbrink et al., 2005; Schu¨ttelkopf
and van Aalten, 2004). We used explicit model for water SPC.We used genbox
to embed theMOR1 receptor in a pre-equilibrated DPPCbilayer. To ensure the
packing of lipids around the receptor,we initially imposed harmonic constraints
(force constant 1000 kJ mol1nm2) on the receptor and performed short
0.5 ns simulation run to equilibrate the lipids. The force constant is sequentially
lowered to 500 kJ mol1nm2, 200 kJ mol1nm2, and 100 kJ mol1nm2,
each time performing a short 0.5 ns simulation. Finally, we performed a pro-
duction run of 20 ns without constraints. Long-range electrostatics is treated
with Particle Mesh Ewald with a grid spacing of 12 A˚ and a cutoff of 10 A˚.
Drug Screening
We screened the clean-lead subset of ZINC database retrieved on January 23,
2009. This subset contains 1,296,388 compound structures in ready-to-dock
format. For the receptor structure used in the docking, we used a conformation
derived from MD simulations with morphine bound. Specifically, we clustered
the MD derived snapshots and used the centroid of the largest cluster. We
applied Autodock4 for docking calculation, which uses genetic algorithm
(GA) and force field-based scoring function to search for best binding poses
(Morris et al., 2009). We prepared the docking grid and parameters using
AutoDockTools (Morris et al., 2009). We used the default docking parameters
except for the number of maximum GA evaluations (increased to 1,750,000)
and the size of GA population (increased to 150). For eachmolecule, we gener-
ated 30 docking poses and assigned the one with lowest binding energy as the
final docking pose. We tested the parameters by redocking the morphine
molecules to recapitulate the pose observed in the MD simulation. The
screening was performed in a Linux cluster using 500 CPU nodes in average
(the Topsail cluster in University of North Carolina at Chapel Hill).Structure 19, 1683–16Binding and cAMP Assays
Mutants were generated by overlapping polymerase chain reaction approach.
Radioligand binding assays were performed using established protocols
(Huang et al., 2009). Briefly, membrane preparations containing recombinant
receptor were incubated with [3H]diprenorphine in the presence of varying
concentrations of putative ligand. After 1 hr, assays were harvested onto
Wallac GF/A filtermats using a Filtermate harvester (Perkin Elmer). Then,
Meltilex scintillant (Wallac) were melted onto dried filtermats and residual
bound radioligand were measured by scintillation counting in TriLux microbeta
counter (Wallac). Monitoring of intracellular cAMP levels were performed using
the GloSensor cAMP-sensitive luciferase reporter (Promega). Briefly, cells
coexpressing GloSensor-22F and receptor isoforms were seeded in white,
384-well plates for 24 hr. The next day, the medium were replaced with
GloSensor reagent (Promega), and incubated for 2 hr. Then, cells were chal-
lenged with morphine at various concentrations. After 5 min, the cells were
stimulated with 100 nM isoproterenol and luminescence was read on a Victor3
(Perkin Elmer) plate counter. When antagonist treatment is done, cells were
pretreated with the antagonist compounds for 30 min prior to morphine and
isoproterenol treatment.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and four tables and can be
found with this article online at doi:10.1016/j.str.2011.08.003.
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